Fresenius Medical Care underlines commitment towards gender equity in the workplace, signing United Nations Women’s Empowerment Principles

The Women’s Empowerment Principles (WEPs) are a set of seven principles offering guidance to business on how to promote gender equity and women’s empowerment in the workplace, marketplace and community. The WEPs are informed by international labor and human rights standards and grounded in the recognition that businesses have a stake in, and a responsibility for, gender equity and women’s empowerment.

Helen Giza, CEO of Fresenius Medical Care, said: “In signing the UN Women’s Empowerment Principles, Fresenius Medical Care is demonstrating its commitment to supporting women throughout their careers by ensuring they have equitable opportunities in a diverse and inclusive work culture; and supporting women in our business processes and in the communities we serve.”

Today’s announcement is another sign of the Company’s ongoing commitment towards diversity, equity, and inclusion. In 2022, the Company has set itself new gender diversity targets to support the development of female leaders across the company.

By 2027, Fresenius Medical Care aims to increase the share of female leaders in the first level below the Management Board to 35%, and the share of female leaders in the second level to 45%. In 2022, the proportion of women in the first two levels below the Management Board was 30%. Moreover, the Company has set itself the goal of increasing the overall representation of women in management positions to reflect the percentage of women in the global employee population by 2030. The new targets were published in its 2022 Non-financial Group Report.

Disclaimer:

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to COVID-19, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forwardlooking statements in this release.